Alio

?? New Manuscript ?? A recently accepted manuscript in the Clinical Kidney Journal, titled Remote Management of Anaemia in Patients with End-Stage Kidney Disease Using a Wearable, Non-Invasive Sensor, highlights the innovative approach Alio is taking to improve patient care. Key points from the manuscript: ?? Across a diverse patient population, the SmartPatch demonstrated close alignment with Hb and Hct levels obtained from gold standard blood draw measurements. ?? When considered alongside data from previous studies on FDA-cleared non-invasive Hb and Hct devices, the SmartPatch showed superior accuracy compared to other similar devices. ?? High-frequency, remote monitoring by the SmartPatch could enable better management of Hb variability, optimizing ESA dosing and reducing the risks associated with Hb cycling, much like how CGMs have improved diabetes care. ?? The SmartPatch aligns with the growing trend toward home dialysis by offering a "set it and forget it" solution, promoting patient-centred care and expanding access to remote anemia management. Find the accepted manuscript here: https://lnkd.in/gm2vw5bV #Alio #CKD #ChronicDiseases #RPM

Our CEO, David Kuraguntla, will be attending the 43rd Annual J.P. Morgan Healthcare Conference next week in San Francisco ??. If you'll be attending and would like to schedule a meeting to catch up on Alio's latest developments, feel free to message us! #ChronicDiseases #RPM #Alio

?? Article of the Month from the VAS Young committee This research article highlights that physical exams, such as HIPA (History, Inspection, Palpation, Auscultation), can be as effective as ultrasound or angiography in detecting stenosis in hemodialysis AV fistulas but are often underutilized. It's exciting to see studies like this emphasize the value of innovations like the SmartPatch ??, which supports this approach by automatically collecting auscultation data and alerting clinicians to atypical acoustic readings, providing early warnings for potential issues and bridging gaps in care. ?? Read more about this publication here: https://lnkd.in/g_B-GWUU #ChronicDiseases #CKD #Alio

Every patient deserves access to quality, patient-centered care. In alignment with the KIDNEY EQUITY FOR ALL movement led by the National Kidney Foundation, we’ve been committed to advancing care that meets the diverse needs of kidney patients everywhere. That’s why we designed the SmartPatch ?? to operate non-invasively and reliably for everyone. Drawing on data collected from over seven countries and thousands of patients worldwide ?? , we validated its ability to adapt seamlessly to all skin types, requiring no calibration while providing trusted, FDA-cleared insights—making care effortless and accessible for all. Learn more and join the National Kidney Foundation's movement by signing their petition to urge policymakers to prioritize kidney health ?? https://lnkd.in/ecVn63PW #KidneyEquityForAll #InclusiveInnovation #Alio

This recent study from Mass General Hospital, published by Nature, shows that patients' typical Complete Blood Count (CBC) values, or 'setpoints,' predict health outcomes better than population averages. Key findings from the study include: ?? Setpoint Stability: CBC setpoints remain stable over decades, even after acute events, and are minimally influenced by age, sex, race, or ethnicity. ?? Disease and Mortality Risk: Long-term outcomes, such as 10-year mortality and risks for diabetes, cardiovascular events, and kidney disease, are better predicted by individual setpoints than by population averages. The SmartPatch, a clinical-grade, non-invasive device, is uniquely positioned to support the evidence presented in this study, advancing individualized health monitoring. It provides a comprehensive view of key hematology parameters, including hemoglobin and hematocrit—two of the most critical indices in a CBC—along with electrolyte levels and other biomarkers. Previous research by Alio has shown our ability to quantify platelets and WBCs, as well. A complete CBC, done non-invasively, may be in the near future. By tracking individual trends and adapting to each patient's unique setpoints, the SmartPatch automatically notifies clinical care teams of subtle changes early, improving chronic condition management in line with the study's findings. ?? To learn more:?https://lnkd.in/g3sNVgQW

?? ?? Happy holidays from Alio ?? ?? Wishing you a holiday season filled with happiness and warmth ?? ? #alio #remotepatientmonitoring #chronicdiseases

Since its introduction, remote patient monitoring (RPM) has been met with thoughtful caution, prompting questions from healthcare teams: 'Can this provide better insights, or will it just contribute to alarm fatigue?' 'Can it fit into our already overburdened workflows? Do we really need more devices?' These concerns are understandable in a system where patient monitoring has long been fragmented and episodic. For decades, monitoring has resembled using multiple polaroid cameras ?? —capturing isolated snapshots like blood tests, vital sign checks, or auditory findings at specific moments. While these snapshots provide valuable data: changes between tests, subtle trends or early warning signs often go unnoticed. Guided by these early conversations, the ?? SmartPatch has helped advance RPM beyond fragmented snapshots from multiple devices. By delivering a real-time, clinical-grade view of hematology parameters, electrolyte levels, and other key biomarkers—all non-invasively and through a single device—it surpasses systems traditionally limited to basic vital sign monitoring. ?? For the healthcare team, our intelligent automation supports personalized care while reducing clinician burden. Wearable sensors collect clinical-grade biometric data ?? Data automatically transmitted to the cloud ?? AI analyzes the data, identifying outliers, complications, and trends ?? Results are integrated into a portal, with automated alerts for clinicians when data falls outside personalized ranges ?? For patients, this means ongoing monitoring with minimal effort. Simply wearing the SmartPatch lets the platform handle the rest. As we look to 2025, we remain committed to personalizing RPM, delivering tailored insights that provide care teams with a clearer, more complete picture of patient health while enhancing the care experience for all.

?? For those living with End-Stage Kidney Disease, their vascular access is essential for effective treatment. Monitoring it closely allows for early interventions, significantly improving outcomes and quality of life. ?? Swipe to learn how the SmartPatch enhances vascular access monitoring and key stats on why this is so important. * doi: 10.1038/s41581-020-0333-2 * doi: 10.1038/s41581-022-00542-7 * doi: 10.1159/000082010

?? Don’t miss Alio's Medical Director, Rajesh Sivaprakasam, presenting tomorrow, December 10th, at the World Summit AI conference in Doha, where he’ll be discussing cutting-edge innovations in healthcare! ? ?? December 10th |???Track 2:?Intelligent Health | ? 12:00 - 12:20 ?? If you’d like to connect with our team during the conference, just send us a message! #Alio #WASI2024 #AI #chronicdiseases #Doha

???The Alio team is excited to attend the World Summit AI conference next week, December 10th and 11th, in Doha! ? ?? Be sure to catch Rajesh Sivaprakasam's presentation, where he’ll share insights into how AI is revolutionizing healthcare: ?? December 10th |???Track 2:?Intelligent Health | ? 12:00 - 12:20 ? Ava Lim and Rajesh Sivaprakasam will be there both days, showcasing how Alio is transforming clinical care for chronic disease management. If you'd like to set up a meeting with our team, feel free to reach out to us on LinkedIn! #Alio #WSAI2024 #AI #chronicdiseases